Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07017270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Study acronym: GUARD-1
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2025 to Nov 27, 2025 · Study sites: 1 to 2 · Secondary endpoints revised (6) · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Jul 2025 to Nov 27, 2025
    • Study sites: 1 to 2
    • Secondary endpoints revised (6)
    • Study description shortened, about 79 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Trial Details
NCT Number NCT07017270
Lead Sponsor Unity Health Toronto
Conditions Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov